Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients

Cancer Med. 2019 Aug;8(9):4089-4092. doi: 10.1002/cam4.2107. Epub 2019 Jun 7.


Patients with myeloproliferative neoplasms (MPN) are known to have higher incidence of nonhematological second primary malignancies (SPM) compared to general population. In the MYSEC study on 781 secondary myelofibrosis (SMF) patients, the incidence of SPM after SMF diagnosis resulted 0.98/100 patient-years. When including non-melanoma skin cancers (NMSC), the incidence arose to 1.56/100 patient-years. In SMF, JAK inhibitor treatment was associated only with NMSC occurrence. Then, we merged the MYSEC cohort with a large dataset of PV and ET not evolving into SMF. In this subanalysis, we did not find any correlation between SPM and SMF occurrence. These findings highlight the need of studies aimed at identifying MPN patients at higher risk of SPM.

Keywords: JAK inhibitors; second malignancy; secondary myelofibrosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cohort Studies
  • Female
  • Humans
  • Incidence
  • Janus Kinase Inhibitors / therapeutic use
  • Male
  • Neoplasms, Second Primary / drug therapy
  • Neoplasms, Second Primary / epidemiology*
  • Polycythemia Vera / drug therapy
  • Polycythemia Vera / epidemiology*
  • Primary Myelofibrosis / drug therapy
  • Primary Myelofibrosis / epidemiology*
  • Skin Neoplasms / epidemiology*
  • Thrombocythemia, Essential / epidemiology*
  • Treatment Outcome


  • Janus Kinase Inhibitors